These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18979581)

  • 21. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
    Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
    Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
    J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2013; 31(5):749-55. PubMed ID: 23806325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor necrosis factor-α monoclonal antibody alleviates parenteral nutrition-associated liver disease in mice.
    Li J; Gong YM; Wu J; Wu WJ; Cai W
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2):219-25. PubMed ID: 22275328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes.
    de Sain-van der Velden MG; Kaysen GA; de Meer K; Stellaard F; Voorbij HA; Reijngoud DJ; Rabelink TJ; Koomans HA
    Kidney Int; 1998 Jan; 53(1):181-8. PubMed ID: 9453016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.
    Miranda-Filloy JA; Llorca J; Carnero-López B; González-Juanatey C; Blanco R; González-Gay MA
    Clin Exp Rheumatol; 2012; 30(6):850-5. PubMed ID: 22765845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
    Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D; Kökönyei G; Arató A; Dezsőfi A; Molnár K; Müller KE; Lakatos PL; Papp M; Lovász BD; Golovics PA; Cseh A; Veres G
    J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated quantitative measurements of De Novo synthesis of albumin and fibrinogen.
    Dumitrescu G; Komaromi A; Rooyackers O; Klaude M; Hebert C; Wernerman J; Norberg Å
    PLoS One; 2017; 12(3):e0174611. PubMed ID: 28350862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease.
    Lee YM; Kang B; Lee Y; Kim MJ; Choe YH
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):737-43. PubMed ID: 25564801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Echocardiographic evaluation of anti-tumor necrosis factor-alpha therapy with infliximab in patients without cardiac pathologies].
    Bragagni G; Lari F; Magenta G; Brogna R; Zoli G
    Recenti Prog Med; 2010; 101(7-8):289-92. PubMed ID: 20842955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy.
    Wiese D; Lashner B; Seidner D
    Nutr Clin Pract; 2008; 23(5):551-6. PubMed ID: 18849561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperadiponectinemia During Infliximab Induction Therapy in Pediatric Crohn Disease.
    Frivolt K; Schwerd T; Schatz SB; Freudenberg F; Prell C; Werkstetter KJ; Bufler P; Koletzko S
    J Pediatr Gastroenterol Nutr; 2018 Jun; 66(6):915-919. PubMed ID: 29287006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scheduled maintenance therapy with infliximab improves the prognosis of Crohn's disease: a single center prospective cohort study in Japan.
    Takahashi S; Takagi S; Shiga H; Umemura K; Endo K; Kakuta Y; Takahashi S; Kinouchi Y; Shimosegawa T
    Tohoku J Exp Med; 2010 Mar; 220(3):207-15. PubMed ID: 20208416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of infliximab in pediatric patients with inflammatory bowel disease.
    Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
    Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Albumin but not fibrinogen synthesis correlates with galactose elimination capacity in patients with cirrhosis of the liver.
    Ballmer PE; Reichen J; McNurlan MA; Sterchi AB; Anderson SE; Garlick PJ
    Hepatology; 1996 Jul; 24(1):53-9. PubMed ID: 8707282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.